Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1334

1.

Does the working channel position have a role on the effectiveness of flexible ureteroscopy? Results from an in vitro study.

Villa L, Ventimiglia E, Proietti S, Giusti G, Briganti A, Salonia A, Montorsi F, Doizi S, Traxer O.

BJU Int. 2019 Oct 14. doi: 10.1111/bju.14923. [Epub ahead of print]

PMID:
31610080
2.

Comprehensive analysis of in-hospital delirium after major surgical oncology procedures.

Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, Montorsi F, Saad F, Shariat SF, Schips L, Briganti A, Karakiewicz PI.

Can Urol Assoc J. 2019 Sep 27. doi: 10.5489/cuaj.6030. [Epub ahead of print]

PMID:
31599720
3.
5.

The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.

Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Moschini M, Zamboni S, Rakauskas A, Tian Z, Karakiewicz PI, De Cobelli F, Porpiglia F, Montorsi F, Briganti A.

Eur Urol. 2019 Sep 21. pii: S0302-2838(19)30694-3. doi: 10.1016/j.eururo.2019.09.005. [Epub ahead of print]

PMID:
31547938
6.

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients.

Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, Bandini M.

Sci Rep. 2019 Sep 13;9(1):13218. doi: 10.1038/s41598-019-49250-6.

7.

Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.

Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30258-7. doi: 10.1016/j.clgc.2019.08.009. [Epub ahead of print]

PMID:
31515197
8.

Long-Term Follow-Up After Penile Prosthesis Implantation-Survival and Quality of Life Outcomes.

Chierigo F, Capogrosso P, Dehò F, Pozzi E, Schifano N, Belladelli F, Montorsi F, Salonia A.

J Sex Med. 2019 Sep 6. pii: S1743-6095(19)31359-1. doi: 10.1016/j.jsxm.2019.08.001. [Epub ahead of print]

PMID:
31501062
9.

Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma.

Palumbo C, Mistretta FA, Knipper S, Mazzone E, Pecoraro A, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lavallee LT, Karakiewicz PI.

Minerva Urol Nefrol. 2019 Sep 4. doi: 10.23736/S0393-2249.19.03496-9. [Epub ahead of print]

PMID:
31487976
10.

Impact of time from diagnosis to treatment on erectile function outcomes after radical prostatectomy.

Schifano N, Capogrosso P, Pozzi E, Ventimiglia E, Cazzaniga W, Matloob R, Gandaglia G, Dehò F, Briganti A, Montorsi F, Salonia A.

Andrology. 2019 Sep 3. doi: 10.1111/andr.12699. [Epub ahead of print]

PMID:
31478610
11.

Is It Compulsory to Investigate for Erectile Dysfunction in Patients Presenting for Low Urinary Tract Symptoms?

Capogrosso P, Boeri L, Pozzi E, Ventimiglia E, Schifano N, Abbate C, Matloob R, Dehò F, Montorsi F, Salonia A.

Eur Urol Focus. 2019 Aug 30. pii: S2405-4569(19)30225-1. doi: 10.1016/j.euf.2019.08.007. [Epub ahead of print]

PMID:
31474582
12.

Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer.

Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Capitanio U, Cucchiara V, Mazzone E, Bravi CA, Mirone V, Montorsi F, Briganti A.

Expert Rev Anticancer Ther. 2019 Sep;19(9):739-755. doi: 10.1080/14737140.2019.1659135. Epub 2019 Aug 30.

PMID:
31469021
13.

Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma.

Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Int Urol Nephrol. 2019 Aug 29. doi: 10.1007/s11255-019-02266-3. [Epub ahead of print]

PMID:
31468289
14.

Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis.

Mazzone E, Knipper S, Mistretta FA, Tian Z, Palumbo C, Soulieres D, De Cobelli O, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

World J Urol. 2019 Aug 28. doi: 10.1007/s00345-019-02927-z. [Epub ahead of print]

PMID:
31463562
15.

How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection.

Zamboni S, Moschini M, Antonelli A, Simeone C, Belotti S, Cristinelli L, Montorsi F, Briganti A, Gallina A, Salonia A, Colombo R, Mordasini L, Mattei A, Baumeister P.

World J Urol. 2019 Aug 28. doi: 10.1007/s00345-019-02916-2. [Epub ahead of print]

PMID:
31463561
16.

Percutaneous Microwave Ablation Versus Cryoablation in the Treatment of T1a Renal Tumors.

De Cobelli F, Papa M, Panzeri M, Colombo M, Steidler S, Ambrosi A, Cao R, Gusmini S, Marra P, Capitanio U, Bertini R, Venturini M, Losa A, Gaboardi F, Montorsi F, Cardone G.

Cardiovasc Intervent Radiol. 2019 Aug 26. doi: 10.1007/s00270-019-02313-7. [Epub ahead of print]

PMID:
31451888
17.

Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.

Cristel G, Esposito A, Damascelli A, Briganti A, Ambrosi A, Brembilla G, Brunetti L, Antunes S, Freschi M, Montorsi F, Del Maschio A, De Cobelli F.

Eur J Radiol. 2019 Sep;118:51-57. doi: 10.1016/j.ejrad.2019.07.002. Epub 2019 Jul 2.

PMID:
31439258
18.

Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in D'Amico Intermediate- and High- Risk Radical Prostatectomy Patients: A Multi-Institutional Study.

Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, Taille A, Briganti A, Salomon L, Ploussard G, Tilki D; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

J Urol. 2019 Aug 22:101097JU0000000000000504. doi: 10.1097/JU.0000000000000504. [Epub ahead of print]

PMID:
31437119
19.

Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology.

Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R.

Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30608-6. doi: 10.1016/j.eururo.2019.07.047. [Epub ahead of print] No abstract available.

PMID:
31420247
20.

Comparison of Two Methods for Assessing Erectile Function Before Radical Prostatectomy.

Bravi CA, Tin A, Benfante N, Salonia A, Briganti A, Montorsi F, Mulhall JP, Eastham JA, Vickers AJ.

Eur Urol Oncol. 2019 Mar 9. pii: S2588-9311(19)30027-6. doi: 10.1016/j.euo.2019.02.003. [Epub ahead of print]

PMID:
31412005
21.

The Impact of Surgical Strategy in Robot-assisted Partial Nephrectomy: Is It Beneficial to Treat Anterior Tumours with Transperitoneal Access and Posterior Tumours with Retroperitoneal Access?

Dell'Oglio P, De Naeyer G, Xiangjun L, Hamilton Z, Capitanio U, Ripa F, Cianflone F, Muttin F, Schatteman P, D'Hondt F, Ma X, Bindayi A, Zhang X, Derweesh I, Mottrie A, Montorsi F, Larcher A; ERUS Educational Working Group and the YAU working group on robot-assisted surgery.

Eur Urol Oncol. 2019 Jan 22. pii: S2588-9311(18)30218-9. doi: 10.1016/j.euo.2018.12.010. [Epub ahead of print]

PMID:
31411997
22.

Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer.

Capitanio U, Larcher A, Cianflone F, Trevisani F, Nini A, Mottrie A, Mari A, Campi R, Tellini R, Briganti A, Veccia A, Van Poppel H, Carini M, Simeone C, Salonia A, Minervini A, Antonelli A, Montorsi F, Bertini R.

Eur Urol Oncol. 2019 Mar 25. pii: S2588-9311(19)30030-6. doi: 10.1016/j.euo.2019.02.006. [Epub ahead of print]

PMID:
31411993
23.

The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.

Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Eur Urol Oncol. 2019 Sep;2(5):541-548. doi: 10.1016/j.euo.2018.10.010. Epub 2018 Nov 22.

PMID:
31411992
24.

Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution.

Bravi CA, Vertosick E, Tin A, Scuderi S, Fallara G, Rosiello G, Mazzone E, Bandini M, Gandaglia G, Fossati N, Freschi M, Montironi R, Briganti A, Montorsi F, Vickers A.

Eur Urol Oncol. 2018 Nov 24. pii: S2588-9311(18)30188-3. doi: 10.1016/j.euo.2018.10.007. [Epub ahead of print]

PMID:
31411978
25.

Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Oncol. 2019 Mar 28. pii: S2588-9311(19)30035-5. doi: 10.1016/j.euo.2019.03.003. [Epub ahead of print]

PMID:
31411975
26.

There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.

Dell'Oglio P, Stabile A, Soligo M, Brembilla G, Esposito A, Gandaglia G, Fossati N, Bravi CA, Dehò F, De Cobelli F, Montorsi F, Karnes RJ, Briganti A.

Eur Urol Oncol. 2019 Mar 27. pii: S2588-9311(19)30033-1. doi: 10.1016/j.euo.2019.03.002. [Epub ahead of print]

PMID:
31411973
27.

Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer.

Martini A, Gandaglia G, Fossati N, Scuderi S, Bravi CA, Mazzone E, Stabile A, Scarcella S, Robesti D, Barletta F, Cucchiara V, Mirone V, Montorsi F, Briganti A.

Eur Urol Oncol. 2019 Apr 4. pii: S2588-9311(19)30039-2. doi: 10.1016/j.euo.2019.03.006. [Epub ahead of print]

PMID:
31411971
28.
29.

Enhanced recovery after surgery (ERAS) in radical cystectomy patients: from consensus to evidences.

Moschini M, Stabile A, Mattei A, Montorsi F, Cathelineau X, Sanchez-Salas R.

Int Braz J Urol. 2019 Jul-Aug;45(4):655-657. doi: 10.1590/S1677-5538.IBJU.2019.04.02. No abstract available.

30.

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes.

Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF.

J Clin Med. 2019 Aug 9;8(8). pii: E1192. doi: 10.3390/jcm8081192.

31.

Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Lattouf JB, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Oct;17(5):e1026-e1035. doi: 10.1016/j.clgc.2019.06.003. Epub 2019 Jun 13.

PMID:
31378580
32.

The emerging role of PET-CT scan after radical prostatectomy: still a long way to go.

Fossati N, Gandaglia G, Briganti A, Montorsi F.

Lancet Oncol. 2019 Sep;20(9):1193-1195. doi: 10.1016/S1470-2045(19)30501-7. Epub 2019 Jul 30. No abstract available.

PMID:
31375470
33.

Consulting "Dr. Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis.

Cacciamani GE, Bassi S, Sebben M, Marcer A, Russo GI, Cocci A, Dell'Oglio P, Medina LG, Nassiri N, Tafuri A, Abreu A, Porcaro AB, Briganti A, Montorsi F, Gill IS, Artibani W.

Eur Urol Oncol. 2019 Jul 30. pii: S2588-9311(19)30105-1. doi: 10.1016/j.euo.2019.07.002. [Epub ahead of print]

PMID:
31375427
34.

Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer.

Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Oct;17(5):e939-e945. doi: 10.1016/j.clgc.2019.05.022. Epub 2019 May 27.

PMID:
31375352
35.

The Modern Western Diet Rich in Advanced Glycation End-Products (AGEs): An Overview of Its Impact on Obesity and Early Progression of Renal Pathology.

Bettiga A, Fiorio F, Di Marco F, Trevisani F, Romani A, Porrini E, Salonia A, Montorsi F, Vago R.

Nutrients. 2019 Jul 30;11(8). pii: E1748. doi: 10.3390/nu11081748. Review.

36.

On-clamp versus off-clamp partial nephrectomy: Propensity score-matched comparison of long-term functional outcomes.

Simone G, Capitanio U, Tuderti G, Presicce F, Leonardo C, Ferriero M, Misuraca L, Costantini M, Larcher A, Minisola F, Guaglianone S, Anceschi U, Muttin F, Nini A, Trevisani F, Montorsi F, Bertini R, Gallucci M.

Int J Urol. 2019 Oct;26(10):985-991. doi: 10.1111/iju.14079. Epub 2019 Jul 24.

PMID:
31342589
37.

Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?

Capitanio U, Montorsi F, Larcher A.

Eur Urol. 2019 Oct;76(4):441-442. doi: 10.1016/j.eururo.2019.07.007. Epub 2019 Jul 18. No abstract available.

PMID:
31327639
38.

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.

Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A; RISC Investigators.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30095-1. doi: 10.1016/j.euo.2019.06.014. [Epub ahead of print]

PMID:
31307962
39.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators.

Eur Urol. 2019 Oct;76(4):425-429. doi: 10.1016/j.eururo.2019.06.032. Epub 2019 Jul 11.

PMID:
31303258
40.

Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer.

Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).

Eur Urol Oncol. 2019 Jul;2(4):456-463. doi: 10.1016/j.euo.2018.12.002. Epub 2018 Dec 24.

PMID:
31277783
41.

Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.

Stabile A, Dell'Oglio P, Soligo M, De Cobelli F, Gandaglia G, Fossati N, Esposito A, Brembilla G, Karnes RJ, Montorsi F, Briganti A.

Eur Urol Oncol. 2019 Jun 13. pii: S2588-9311(19)30073-2. doi: 10.1016/j.euo.2019.05.006. [Epub ahead of print]

PMID:
31204312
42.

Re: Tom A. Hueting, Erik B. Cornel, Diederik M. Somford, et al. External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. Eur Urol Oncol 2018;1:411-7.

Gandaglia G, Montorsi F.

Eur Urol Oncol. 2019 May;2(3):337. doi: 10.1016/j.euo.2019.01.007. Epub 2019 Jan 30. No abstract available.

PMID:
31200850
43.

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.

Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A.

Eur Urol Oncol. 2019 May;2(3):248-256. doi: 10.1016/j.euo.2018.08.009. Epub 2018 Sep 7.

PMID:
31200838
44.

Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy.

Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Lattouf JB, Musi G, Perrotte P, Montanari E, Shariat SF, Montorsi F, Saad F, de Cobelli O, Karakiewicz PI.

Clin Genitourin Cancer. 2019 Aug;17(4):e793-e801. doi: 10.1016/j.clgc.2019.04.015. Epub 2019 Apr 30.

PMID:
31182339
45.

Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?

Montironi R, Cheng L, Scarpelli M, Cimadamore A, Montorsi F, Lopez-Beltran A.

Eur Urol. 2019 Sep;76(3):e69-e72. doi: 10.1016/j.eururo.2019.05.035. Epub 2019 Jun 6. No abstract available.

PMID:
31176624
46.

The role of metastasectomy in advanced renal cell carcinoma.

Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G.

Expert Rev Anticancer Ther. 2019 Jul;19(7):603-611. doi: 10.1080/14737140.2019.1625772. Epub 2019 Jun 8.

PMID:
31159619
47.

Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery.

Capitanio U, Necchi A, Larcher A, De Cobelli F, Montorsi F.

Eur Urol Oncol. 2018 Dec;1(6):538-539. doi: 10.1016/j.euo.2018.06.003. Epub 2018 Jul 2. No abstract available.

PMID:
31158101
48.

A Novel Classification Proposal for Rectourethral Fistulas After Primary Treatment of Prostate Cancer.

Martini A, Gandaglia G, Nicita G, Montorsi F.

Eur Urol Oncol. 2018 Dec;1(6):510-511. doi: 10.1016/j.euo.2018.09.002. Epub 2018 Sep 28. No abstract available.

PMID:
31158096
49.

Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma.

González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G.

Eur J Surg Oncol. 2019 Oct;45(10):1983-1992. doi: 10.1016/j.ejso.2019.05.009. Epub 2019 May 15.

PMID:
31155470
50.

Re: Tea's Value as a Cancer Therapy is Steeped in Uncertainty.

Lavorgna G, Montorsi F, Salonia A.

Eur Urol. 2019 May 27. pii: S0302-2838(19)30421-X. doi: 10.1016/j.eururo.2019.05.017. [Epub ahead of print] No abstract available.

PMID:
31146901

Supplemental Content

Loading ...
Support Center